© 2020 MJH Life Sciences and HCPLive. All rights reserved.
November 17, 2018
Here’s a round-up of recent designations granted by the FDA to products developed to treat rare diseases.
October 24, 2018
September 27, 2018
The FDA recognized the potential of proCase, which is being developed to treat blood clots and does not increase the risk of bleeding.
September 17, 2018
The FDA has granted a fast track designation to miransertib for the treatment of PIK3CA-Related Overgrowth Spectrum, a group of ultra-rare genetic disorders.
September 12, 2018
The FDA has granted a fast track designation to pamrevlumab for the treatment of patients with idiopathic pulmonary fibrosis (IPF).
September 11, 2018
The FDA has granted a fast track designation to Immune Pharmaceuticals, Inc.’s bertilimumab for the treatment of bullous pemphigoid.